STOCK TITAN

AVEO - AVEO STOCK NEWS

Welcome to our dedicated page for AVEO news (Ticker: AVEO), a resource for investors and traders seeking the latest updates and insights on AVEO stock.

AVEO Pharmaceuticals Inc., now operating as AVEO Oncology under LG Chem, is a biopharmaceutical company dedicated to improving the lives of cancer patients through innovative treatments. AVEO's primary focus is on oncology, specifically targeting and commercializing therapies within North America, while leveraging strategic partnerships for development in other regions.

Key product: FOTIVDA® (tivozanib), a next-generation vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitor (TKI), is AVEO’s lead candidate, approved by the U.S. FDA in March 2021 for treating relapsed or refractory renal cell carcinoma (RCC) after two or more prior systemic therapies. It boasts a favorable safety profile and significant long-term survival benefits. Initially approved in the European Union and other countries in 2017, FOTIVDA® continues to show promise in clinical settings, with recent trials indicating its efficacy over sorafenib in patients with advanced RCC.

Alongside FOTIVDA®, AVEO's pipeline includes promising candidates like ficlatuzumab, an anti-HGF IgG1 mAb currently in a Phase 3 trial for head and neck squamous cell carcinoma (HNSCC). The company also explores the potential of AV-380 for treating cancer cachexia, supported by a Phase 1 clinical trial. Other early-stage monoclonal antibodies in development include AV-203 targeting ErbB3 and AV-353 targeting Notch 3.

Recent updates include the commencement of the FIERCE-HN trial, evaluating ficlatuzumab in combination with ERBITUX® for HPV-negative recurrent or metastatic HNSCC, and the release of a significant post-hoc analysis from the TIVO-3 trial, reinforcing FOTIVDA®'s durable clinical benefits.

AVEO's commitment to diversity and inclusion, coupled with rigorous scientific research and development under the aegis of LG Chem, underscores its mission to deliver life-enhancing oncology treatments globally.

Rhea-AI Summary
AVEO Oncology appoints Dr. Edgar E. Braendle as Chief Medical Officer and forms a Scientific Advisory Committee with top oncology experts. Dr. Braendle brings extensive clinical research experience to AVEO, enhancing drug development initiatives.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
management
-
Rhea-AI Summary
AVEO Oncology appoints Dr. Edgar E. Braendle as Chief Medical Officer and forms Scientific Advisory Committee with renowned experts in oncology research.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
management
-
Rhea-AI Summary
AVEO Oncology, an LG Chem company, announced the publication of a post-hoc analysis of long-term progression-free survival, overall survival, and safety data from the Phase 3 TIVO-3 trial evaluating FOTIVDA in patients with relapsed or refractory advanced renal cell carcinoma. The analysis showed a consistent safety profile and long-term survival benefit in patients, indicating a durable clinical benefit and safety across age groups regardless of prior treatment. TIVO-3 compared the efficacy and safety of FOTIVDA and sorafenib in patients with advanced RCC, with FOTIVDA demonstrating higher long-term progression-free survival rates and overall survival benefit compared to sorafenib. The study showed lower treatment-related adverse events and dose modification rates with FOTIVDA, highlighting its potential as a safe and effective therapy for patients with refractory RCC.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
Rhea-AI Summary
AVEO Oncology, an LG Chem company, has announced the enrollment of the first patient in the FIERCE-HN trial, a phase 3 clinical trial evaluating ficlatuzumab in combination with ERBITUX for the treatment of HPV-negative recurrent or metastatic head and neck squamous cell carcinoma. The trial follows FDA Fast Track Designation and aims to improve survival outcomes in an underserved patient population.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags

FAQ

What is AVEO Pharmaceuticals' primary focus?

AVEO Pharmaceuticals is focused on oncology, developing and commercializing cancer treatments such as FOTIVDA® for renal cell carcinoma.

What is FOTIVDA®?

FOTIVDA® (tivozanib) is an oral VEGFR tyrosine kinase inhibitor approved for treating relapsed or refractory renal cell carcinoma.

What recent trials has AVEO conducted?

AVEO recently initiated the FIERCE-HN trial for ficlatuzumab combined with ERBITUX® in head and neck cancer and published a post-hoc analysis of the TIVO-3 trial for FOTIVDA®.

What are the key features of FOTIVDA®?

FOTIVDA® is known for its selective inhibition of VEGFRs, long-term survival benefits, and favorable safety profile in treating advanced renal cell carcinoma.

What other products are in AVEO's pipeline?

AVEO's pipeline includes ficlatuzumab for head and neck cancer, AV-380 for cancer cachexia, and early-stage monoclonal antibodies like AV-203 and AV-353.

What is the significance of the FIERCE-HN trial?

The FIERCE-HN trial is a global Phase 3 study evaluating ficlatuzumab with ERBITUX® for HPV-negative head and neck squamous cell carcinoma.

How does AVEO leverage partnerships?

AVEO collaborates with partners to support the development and commercialization of its products in geographic regions outside North America.

What is the role of LG Chem in AVEO's operations?

LG Chem, which acquired AVEO, provides support in pharmaceuticals development and commercialization, enhancing AVEO's ability to deliver innovative cancer treatments.

What safety precautions are associated with FOTIVDA®?

FOTIVDA®'s safety profile includes monitoring for hypertension, cardiac events, thromboembolic events, proteinuria, thyroid dysfunction, and impaired wound healing.

Where can patients and healthcare providers find more information about FOTIVDA®?

Detailed prescribing information for FOTIVDA® is available on AVEO Oncology’s website and through healthcare providers.

AVEO

Nasdaq:AVEO

AVEO Rankings

AVEO Stock Data

521.45M
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
Boston